Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy

Summary Background Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. Aim To assess the disease course and frequency of relapse of Crohn's disease (CD) following discontinuation of biological...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Alimentary pharmacology & therapeutics Ročník 37; číslo 2; s. 225 - 233
Hlavní autoři: Molnár, T., Lakatos, P. L., Farkas, K., Nagy, F., Szepes, Z., Miheller, P., Horváth, G., Papp, M., Palatka, K., Nyári, T., Bálint, A., Lőrinczy, K., Wittmann, T.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Oxford Blackwell 01.01.2013
Témata:
Adalimumab
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Biological and medical sciences
Biological Therapy - methods
Crohn Disease - diagnosis
Crohn Disease - drug therapy
Digestive system
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Agents - therapeutic use
Humans
Infliximab
Logistic Models
Male
Medical sciences
Middle Aged
Other diseases. Semiology
Pharmacology. Drug treatments
Predictive Value of Tests
Recurrence
Remission Induction
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Time Factors
Young Adult
Human
Crohn disease
Relapse
Biotherapy
Biological response modifier
Digestive diseases
Intestinal disease
Remission
Predictive factor
Inflammatory disease
ISSN:0269-2813, 1365-2036, 1365-2036
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Summary Background Some of the most important questions relating to the use of biological therapy in inflammatory bowel diseases concern the duration of maintenance therapy. Aim To assess the disease course and frequency of relapse of Crohn's disease (CD) following discontinuation of biological therapy, and to determine predictive factors for relapse. Methods One hundred twenty‐one CD patients who had achieved clinical remission following 1 year of biological therapy and for whom biological therapy was then discontinued participated in this prospective observational study. Eighty‐seven CD patients had received infliximab and 34 adalimumab. The definition of relapse was an increase of >100 points in CDAI to at least a CDAI of 150 points. Results Biological therapy was restarted within 1 year of treatment cessation in 45% of patients. Logistic regression analysis revealed that previous biological therapy (P = 0.011) and dose intensification during the 1‐year course of biological therapy (P = 0.024) were associated with the need for and the time to the restarting of biological therapy. Smoking was observed to have an effect that was not statistically significant (P = 0.053). Conclusions Biological therapy was restarted a median of 6 months after discontinuation in almost half of Crohn's disease patients in who had been in clinical remission following 1 year of biological therapy. These results suggest that, in the event of the presence of certain predictive factors, biological therapy should probably be continued for more than 1 year by most patients.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0269-2813
1365-2036
1365-2036
DOI:10.1111/apt.12160